(firstQuint)Neihulizumab (AbGn-168H) in Patients With Steroid-refractory Acute Graft-versus-host Disease.

 This study is a Phase I, single dose, dose-escalation study to study the pharmacokinetics, safety, signs of efficacy, receptor occupancy and pharmacodynamics biomarkers (REG3-alpha and ST2 of Neihulizumab in patients with steroid-refractory acute GvHD.

 Up to 24 patients will be recruited in 4-9 clinical centers in US.

.

 Neihulizumab (AbGn-168H) in Patients With Steroid-refractory Acute Graft-versus-host Disease@highlight

To establish the pharmacokinetic, pharmacodynamic, safety and efficacy profiles of Neihulizumab in patients with steroid-refractory acute graft-versus-host disease(sr-aGvHD)